PTC Therapeutics (PTCT) Stock Price

PTC Therapeutics Price

NASDAQ·CLOSED
73.71USD+0.40 (+0.54 %)
Market closed

Revenue has compounded at 48.3% per year over the past 23 years to 1.73 B USD. PTC Therapeutics's net margin stands at 39.4%, up from -97.3% several years earlier. Analysts set a median price target of 88.74 USD, implying 20.4% above the current price. Of 22 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 63% above its 52-week low.

PTC Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of PTC Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how PTC Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing PTC Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

PTC Therapeutics Stock Price History
DatePTC Therapeutics Price
8/10/202673.71 USD
8/7/202673.31 USD
8/6/202670.85 USD
8/5/202669.08 USD
8/4/202669.36 USD
8/3/202668.11 USD
7/31/202668.01 USD
7/30/202675.52 USD
7/29/202674.81 USD
7/27/202676.69 USD
7/23/202678.45 USD
7/22/202678.40 USD
7/21/202678.50 USD
7/20/202678.01 USD
7/17/202678.59 USD
7/16/202678.52 USD
7/15/202678.84 USD
7/14/202678.06 USD
7/13/202681.88 USD
7/10/202684.85 USD
7/9/202689.55 USD
7/8/202689.18 USD
7/7/202689.20 USD
7/6/202684.22 USD
7/2/202683.31 USD
7/1/202681.35 USD
6/30/202681.57 USD
6/29/202680.98 USD
6/26/202684.43 USD
6/25/202684.51 USD
6/24/202684.41 USD
6/23/202682.13 USD
6/22/202681.05 USD
6/18/202678.36 USD
6/17/202678.91 USD
6/16/202674.13 USD
6/15/202673.07 USD
6/12/202675.63 USD
6/11/202674.53 USD
6/10/202674.09 USD
6/9/202673.68 USD
6/8/202670.87 USD
6/5/202672.15 USD
6/4/202670.69 USD
6/3/202668.93 USD
6/2/202670.02 USD
6/1/202672.40 USD
5/29/202672.65 USD
5/28/202670.32 USD
5/27/202670.76 USD
5/26/202667.60 USD
5/22/202668.39 USD
5/21/202669.80 USD
5/20/202671.28 USD
5/19/202670.31 USD
5/18/202670.15 USD
5/15/202671.47 USD
5/14/202672.72 USD
5/13/202673.46 USD
5/12/202675.02 USD
5/11/202676.85 USD
5/8/202673.69 USD
5/7/202664.49 USD
5/6/202666.57 USD
5/5/202665.04 USD
5/4/202665.49 USD
5/1/202665.15 USD
4/30/202665.06 USD
4/29/202664.55 USD
4/28/202670.26 USD
4/27/202669.22 USD
4/24/202668.23 USD
4/23/202668.59 USD
4/22/202670.85 USD
4/21/202670.63 USD
4/20/202672.32 USD
4/17/202672.43 USD
4/16/202671.70 USD
4/15/202673.57 USD
4/14/202673.01 USD
4/13/202670.42 USD
4/10/202668.69 USD
4/9/202670.85 USD
4/8/202671.26 USD
4/7/202669.58 USD
4/6/202668.90 USD
4/2/202667.77 USD
4/1/202668.75 USD
3/31/202668.13 USD
3/30/202665.64 USD
3/27/202666.13 USD
3/26/202667.00 USD
3/25/202666.75 USD
3/24/202664.54 USD
3/23/202666.42 USD
3/20/202665.30 USD
3/19/202667.08 USD
3/18/202667.00 USD
3/17/202667.45 USD
3/16/202666.71 USD
3/13/202664.49 USD
3/12/202663.36 USD
3/11/202665.67 USD
3/10/202668.56 USD
3/9/202668.40 USD
3/6/202662.82 USD
3/5/202663.33 USD
3/4/202664.29 USD
3/3/202664.39 USD
3/2/202666.37 USD
2/27/202668.19 USD
2/26/202668.10 USD
2/25/202667.76 USD
2/24/202668.98 USD
2/23/202670.50 USD
2/20/202670.66 USD
2/19/202669.90 USD
2/18/202668.93 USD
2/17/202669.17 USD
2/13/202669.45 USD
2/12/202670.70 USD
2/11/202670.92 USD
2/10/202672.14 USD
2/9/202674.16 USD
2/6/202674.68 USD
2/5/202672.36 USD
2/4/202673.91 USD
2/3/202674.83 USD
2/2/202674.88 USD
1/30/202675.53 USD
1/29/202676.43 USD
1/28/202675.60 USD
1/27/202675.49 USD
1/26/202676.23 USD
1/23/202675.25 USD
1/22/202676.17 USD
1/21/202675.56 USD
1/20/202673.07 USD
1/16/202672.48 USD
1/15/202675.64 USD
1/14/202677.29 USD
1/13/202675.40 USD
1/12/202677.59 USD
1/9/202677.53 USD
1/8/202676.85 USD
1/7/202677.24 USD
1/6/202676.70 USD
1/5/202676.76 USD
1/2/202676.74 USD
12/31/202575.96 USD
12/30/202576.19 USD
12/29/202577.64 USD
12/26/202578.56 USD
12/24/202578.37 USD
12/23/202577.70 USD
12/22/202578.90 USD
12/19/202578.57 USD
12/18/202574.59 USD
12/17/202574.94 USD
12/16/202575.42 USD
12/15/202576.25 USD
12/12/202575.64 USD
12/11/202575.44 USD
12/10/202574.10 USD
12/9/202573.47 USD
12/8/202576.91 USD
12/5/202577.26 USD
12/4/202577.85 USD
12/3/202575.76 USD
12/2/202578.50 USD
12/1/202579.20 USD
11/28/202585.99 USD
11/26/202586.25 USD
11/25/202582.93 USD
11/24/202579.83 USD
11/21/202578.47 USD
11/20/202576.46 USD
11/19/202575.60 USD
11/18/202576.69 USD
11/17/202575.60 USD
11/14/202575.30 USD
11/13/202574.95 USD
11/12/202574.95 USD
11/11/202573.82 USD
11/10/202572.48 USD
11/7/202571.78 USD
11/6/202572.59 USD
11/5/202571.77 USD
11/4/202567.72 USD
11/3/202567.93 USD
10/31/202568.31 USD
10/30/202568.11 USD
10/29/202567.35 USD
10/28/202567.49 USD
10/27/202567.08 USD
10/24/202566.40 USD
10/23/202566.80 USD
10/22/202566.52 USD
10/21/202567.17 USD
10/20/202568.36 USD
10/17/202565.95 USD
10/16/202566.82 USD
10/15/202568.51 USD
10/14/202566.09 USD
10/13/202566.06 USD
10/10/202566.23 USD
10/9/202566.01 USD
10/8/202564.48 USD
10/7/202563.91 USD
10/6/202564.80 USD
10/3/202565.37 USD
10/2/202563.02 USD
10/1/202562.01 USD
9/30/202561.37 USD
9/29/202560.65 USD
9/26/202558.99 USD
9/25/202557.84 USD
9/24/202559.50 USD
9/23/202560.56 USD
9/22/202560.85 USD
9/19/202560.48 USD
9/18/202562.88 USD
9/17/202560.65 USD
9/16/202559.69 USD
9/15/202558.98 USD
9/12/202561.09 USD
9/11/202560.96 USD
9/10/202558.33 USD
9/9/202558.42 USD
9/8/202556.95 USD
9/5/202557.26 USD
9/4/202558.01 USD
9/3/202555.55 USD
9/2/202552.43 USD
8/29/202549.33 USD
8/28/202549.79 USD
8/27/202549.78 USD
8/26/202549.46 USD
8/25/202549.30 USD
8/22/202550.57 USD
8/21/202548.92 USD
8/20/202548.85 USD
8/19/202549.59 USD
8/18/202549.80 USD
8/15/202548.82 USD
8/14/202548.70 USD
8/13/202548.17 USD
8/12/202545.27 USD
Access this data via the Eulerpool API
Get Free API Key

PTC Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
937.82 M USD
-566.93 M USD
-626.60 M USD
Jan 1, 2024
806.78 M USD
-196.13 M USD
-363.30 M USD
Jan 1, 2025
1.73 B USD
856.51 M USD
682.64 M USD
Jan 1, 2026 (e)
1.18 B USD
-442.41 M USD
46.62 M USD
Jan 1, 2027 (e)
1.34 B USD
-502.68 M USD
206.94 M USD
Jan 1, 2028 (e)
1.59 B USD
-594.76 M USD
368.57 M USD
Jan 1, 2029 (e)
1.76 B USD
-659.75 M USD
364.52 M USD
Jan 1, 2030 (e)
1.92 B USD
-719.58 M USD
462.07 M USD

PTC Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 4:56 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.040.080.190.260.310.380.540.700.940.811.731.181.341.591.761.92
63.64127.78136.5936.0815.9124.1841.5829.7434.24-13.98114.64-31.6813.6218.3210.959.08
100.00100.0097.4295.4596.0895.0094.0593.7093.0692.9395.8495.8495.8495.8495.8495.84
0.040.080.190.250.290.360.510.650.870.751.661.131.291.521.691.84
-167.00-133.00-65.00-115.00-241.00-431.00-432.00-496.00-566.00-196.00856.00-442.00-502.00-594.00-659.00-719.00
-463.89-162.20-33.51-43.56-78.76-113.42-80.30-71.06-60.41-24.3249.48-37.39-37.38-37.38-37.38-37.39
-170.00-142.00-79.00-128.00-251.00-438.00-523.00-559.00-626.00-363.00682.0046.00206.00368.00364.00462.00
82.80-16.47-44.3762.0396.0974.5019.416.8811.99-42.01-287.88-93.26347.8378.64-1.0926.92
33.9234.1741.9750.3756.5766.8370.6772.6675.5177.2080.6980.6980.6980.6980.6980.69
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales PTC Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue PTC Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare PTC Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares PTC Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against PTC Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

PTC Therapeutics stock margins

The PTC Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PTC Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PTC Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
94.00 %
-80.27 %
-97.27 %
Jan 1, 2022
93.61 %
-71.07 %
-80.00 %
Jan 1, 2023
93.02 %
-60.45 %
-66.81 %
Jan 1, 2024
92.89 %
-24.31 %
-45.03 %
Jan 1, 2025
95.85 %
49.49 %
39.44 %
Jan 1, 2026 (e)
95.85 %
-37.41 %
3.94 %
Jan 1, 2027 (e)
95.85 %
-37.41 %
15.40 %
Jan 1, 2028 (e)
95.85 %
-37.41 %
23.18 %

PTC Therapeutics Stock Revenue, EBIT, Earnings per Share

The PTC Therapeutics earnings per share therefore indicates how much revenue PTC Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
7.62 USD
-6.12 USD
-7.41 USD
Jan 1, 2022
9.62 USD
-6.84 USD
-7.69 USD
Jan 1, 2023
12.42 USD
-7.51 USD
-8.30 USD
Jan 1, 2024
10.45 USD
-2.54 USD
-4.71 USD
Jan 1, 2025
21.45 USD
10.61 USD
8.46 USD
Jan 1, 2026 (e)
14.73 USD
-5.48 USD
0.58 USD
Jan 1, 2027 (e)
16.74 USD
-6.23 USD
2.58 USD
Jan 1, 2028 (e)
19.80 USD
-7.37 USD
4.59 USD

PTC Therapeutics business model & stock analysis

PTC Therapeutics Inc. is a biopharmaceutical company based in South Plainfield, New Jersey. The company was founded in 1998 and focuses on the research and development of drugs for the treatment of rare diseases. The company has two main divisions: product research and development, and science and innovation. Its product range includes several drugs for the treatment of rare diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and cystic fibrosis. One of its key products is Translarna, the first RNA-targeted drug approved for the treatment of Duchenne muscular dystrophy. Another product is Evrysdi, approved for the treatment of spinal muscular atrophy. PTC Therapeutics also has a pipeline of drugs being tested in clinical trials for various rare diseases. The company is committed to promoting innovation and has partnerships with academic institutions and other companies to explore and develop new therapies. Overall, PTC Therapeutics aims to improve the lives of patients with rare diseases through innovative treatments.

PTC Therapeutics SWOT Analysis

Strengths

PTC Therapeutics Inc possesses several strengths that contribute to its competitive position and growth potential. These strengths include:

  • Strong Research and Development Capabilities: PTC Therapeutics Inc has a robust R&D division, allowing it to innovate and develop new drugs and therapies.
  • Patented Technologies: The company owns several patented technologies, providing it with a competitive advantage and potential revenue streams.
  • Strategic Partnerships: PTC Therapeutics Inc has established partnerships with leading pharmaceutical companies, enhancing its market reach and access to resources.
  • Diverse Product Pipeline: The company has a diverse portfolio of products in various stages of development, reducing dependency on a single drug.

Weaknesses

Despite its strengths, PTC Therapeutics Inc faces certain weaknesses that may impact its performance and market position. These weaknesses include:

  • Dependency on a Few Key Products: The success of PTC Therapeutics Inc heavily relies on a few key products, making it vulnerable to market uncertainties or failures in development.
  • Limited Market Presence: Compared to some of its competitors, the company has a relatively smaller market presence, constraining its market reach and visibility.
  • Regulatory Challenges: The pharmaceutical industry is subject to stringent regulatory requirements, and any regulatory hurdles can delay product approvals and impact the company's timelines.

Opportunities

PTC Therapeutics Inc can leverage various opportunities to expand its market share and drive growth. These opportunities include:

  • Emerging Markets: The company can explore untapped emerging markets, expanding its customer base and revenue streams.
  • Advancements in Genetic Therapies: With increasing advancements in genetic therapies, PTC Therapeutics Inc can capitalize on this growing market and develop targeted treatments.
  • Strategic Acquisitions: The company can consider strategic acquisitions to augment its product pipeline, enhance research capabilities, and gain access to new markets.

Threats

PTC Therapeutics Inc is exposed to several threats that may hinder its growth and competitiveness. These threats include:

  • Intense Competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share, which may impact pricing and market penetration.
  • Pricing Pressures: Healthcare cost containment measures and pricing pressures can affect the profitability of PTC Therapeutics Inc's products.
  • Intellectual Property Challenges: The company may face patent disputes or challenges from competitors, jeopardizing its exclusive rights to key technologies.

PTC Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

PTC Therapeutics Employees
Details
Date
PTC Therapeutics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

PTC Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

PTC Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

PTC Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

PTC Therapeutics shares outstanding

The number of shares of PTC Therapeutics was 80.69 M in 2025. This indicates how many shares PTC Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
70.67 M Stocks
Jan 1, 2022
72.66 M Stocks
Jan 1, 2023
75.51 M Stocks
Jan 1, 2024
77.20 M Stocks
Jan 1, 2025
80.69 M Stocks
Jan 1, 2026 (e)
80.69 M Stocks
Jan 1, 2027 (e)
80.69 M Stocks
Jan 1, 2028 (e)
80.69 M Stocks

Current PTC Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.16 %
Buy
72.73 % (16)
Hold
22.73 % (5)
Sell
4.55 % (1)
12M Price Target
88.74
Last Price
73.71
Currency
USD
12M Return Potential
20.40 %
LTM Return
0 %

PTC Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
7/31/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
7/31/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight60
7/20/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
7/16/2026
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
7/7/2026
RBC Capital
RBC Capital
MaintainedSector Perform52
5/27/2026
Jefferies
Jefferies
UpgradeHoldBuy47
5/8/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
5/8/2026
TD Cowen
TD Cowen
UpgradeHoldBuy60
5/8/2026
RBC Capital
RBC Capital
MaintainedSector Perform52
3/30/2026
Jefferies
Jefferies
DowngradeBuyHold47

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

PTC Therapeutics Earnings Calls

2025

PTC Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/20260.33USD-299.26 MUSD-2026 Q2
5/4/2026-0.49USD-227.80 MUSD-2026 Q1
2/24/20260.04USD-282.20 MUSD-2025 Q4
4/25/2024-0.99USD-191.24 MUSD-2024 Q1
2/19/20240.36USD-313.48 MUSD-2023 Q4
8/2/2023-1.62USD-190.73 MUSD-2023 Q2
5/1/2023-1.45USD-201.59 MUSD-2023 Q1
2/20/2023-1.39USD-206.66 MUSD-2022 Q4
10/27/2022-1.27USD-189.70 MUSD-2022 Q3
8/4/2022-1.36USD-164.52 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the PTC Therapeutics stock

48/100
24
Environment
62
Social
59
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

PTC Therapeutics shareholder structure

% Name
16.12743%
BLACKROCK, INC.
BLACKROCK, INC.
9.64804%
RTW INVESTMENTS, LP
RTW INVESTMENTS, LP
8.95931%
JANUS HENDERSON GROUP PLC
JANUS HENDERSON GROUP PLC
5.98405%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
5.41352%
STATE STREET CORP
STATE STREET CORP
4.91046%
WELLINGTON MANAGEMENT GROUP LLP
WELLINGTON MANAGEMENT GROUP LLP
...

PTC Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
88.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
16.20%
Complete Pharma Holdings II, LLC
Complete Pharma Holdings II, LLC
SEC ↗
14.80%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
10.54%
FMR LLC
FMR LLC
SEC ↗
10.54%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
10.06%
HBM Healthcare Investments (Cayman) Ltd.
HBM Healthcare Investments (Cayman) Ltd.
SEC ↗
9.90%
Scopia Management, Inc.
Scopia Management, Inc.
SEC ↗
9.90%
Matthew Sirovich
Matthew Sirovich
SEC ↗
9.90%
Jeremy Mindich
Jeremy Mindich
SEC ↗
9.56%
PTC Therapeutics, Inc.
PTC Therapeutics, Inc.
SEC ↗
9.47%
RTW Master Fund, Ltd.
RTW Master Fund, Ltd.
SEC ↗

PTC Therapeutics Executives and Management Board

16 members · avg. age 62 · 31 % women

MK

Dr. Matthew Klein (53)

President, Chief Executive Officer, Director · since 2020

7.41 M USD

Management

EP

Mr. Eric Pauwels (64)

Chief Business Officer

2.40 M USD
NA

Dr. Neil Almstead (58)

Chief Technical Operations Officer

2.32 M USD
LG

Dr. Lee Golden (57)

Executive Vice President, Chief Medical Officer

2.25 M USD
PG

Mr. Pierre Gravier (40)

Chief Financial Officer

2.23 M USD
MB

Mr. Mark Boulding (64)

Executive Vice President, Chief Legal Officer

2.19 M USD
CU

Ms. Christine Utter (47)

Senior Vice President, Chief Accounting Officer, Head - People Services

1.70 M USD

Board of Directors

MS

Mr. Michael Schmertzler (73)

Independent Chairman of the Board

551,016.00 USD
AJ

Dr. Allan Jacobson (79)

Independent Director

377,675.00 USD
ER

Ms. Emma Reeve (64)

Independent Director

330,175.00 USD
DS

Mr. David Southwell (64)

Independent Director

317,175.00 USD
AY

Ms. Alethia Young (46)

Independent Director

313,675.00 USD
MS

Ms. Mary Smith (62)

Independent Director

309,675.00 USD

Frequently asked questions about PTC Therapeutics

PTC Therapeutics Inc.'s business model revolves around researching, developing, and commercializing innovative therapies for rare genetic disorders. The company focuses on utilizing its expertise in RNA biology and small molecule pharmacology to develop treatments that address the underlying cause of diseases. PTC Therapeutics Inc. aims to increase the production of functional proteins in patients with genetic disorders by targeting RNA splicing or protein translational regulation. Through strategic partnerships, clinical trials, and regulatory approvals, PTC Therapeutics Inc. strives to bring transformative treatments to patients with limited therapeutic options, ultimately improving their quality of life.

PTC Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of PTC Therapeutics Inc in the market are companies like Sarepta Therapeutics, Vertex Pharmaceuticals, and BioMarin Pharmaceutical.

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered small molecule drugs. Founded in 1998, PTC Therapeutics initially focused on RNA biology and identified a new class of RNA-modulating small molecules. Since its inception, the company has been committed to addressing the unmet medical needs of patients with rare and genetic disorders. Today, PTC Therapeutics is a global leader in the development of treatments for rare diseases, with a portfolio that includes multiple therapies targeting various genetic mutations. Through its innovative approach, PTC Therapeutics aims to improve the lives of patients worldwide.

PTC Therapeutics Inc has achieved several significant milestones. One notable accomplishment includes the approval of their drug, Translarna™ (ataluren), by the European Medicines Agency (EMA). This groundbreaking treatment is designed to address the underlying cause of nonsense mutation Duchenne muscular dystrophy (nmDMD). Additionally, PTC Therapeutics Inc has successfully expanded its global footprint by establishing commercialization agreements for Translarna™ in various countries. These achievements highlight PTC Therapeutics Inc's commitment to advancing innovative therapies and improving the lives of patients with genetic disorders like nmDMD.

PTC Therapeutics Inc is primarily present in various countries and regions across the globe. As a pharmaceutical company, PTC Therapeutics Inc operates in multiple markets to ensure patient access to its innovative therapies. The company's presence extends to regions such as North America, including the United States and Canada, as well as Europe, with a focus on countries like Germany, France, and Italy. PTC Therapeutics Inc continues to expand its presence in other international markets, driven by its commitment to improving the lives of patients worldwide.

PTC Therapeutics Inc represents core values of innovation, dedication, and patient-centricity. With a strong corporate philosophy, the company is committed to developing transformative therapies for patients with rare diseases caused by genetic mutations. PTC Therapeutics Inc focuses on leveraging cutting-edge science and technology to develop targeted treatments, addressing unmet medical needs. By fostering collaboration and embracing a patient-first approach, PTC Therapeutics Inc strives to improve the quality of life for individuals and families affected by these rare and debilitating conditions. Through their relentless pursuit of scientific advancements, PTC Therapeutics Inc demonstrates their commitment to making a meaningful difference in the lives of patients worldwide.

Analysts currently set an average price target of 89.01 USD for the PTC Therapeutics stock (median: 88.74 USD), implying +20.8 % versus the latest price. The consensus is based on 22 analyst ratings.

PTC Therapeutics Analyst Price Targets 2026

22 analysts currently rate the PTC Therapeutics stock: 16 recommend buying, 5 holding and 1 selling. For 2026, analysts expect PTC Therapeutics to generate revenue of 1.18 B USD and earnings per share of 0.58 USD.

PTC Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the PTC Therapeutics share trades at 63.86 EUR (73.71 USD).

The PTC Therapeutics share (PTCT) is listed on 5 stock exchanges, including: NASDAQ (PTCT), Frankfurt (BH3.F), München (BH3.MU), Düsseldorf (BH3.DU), SIX (Zürich) (P91.SW).

PTC Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for rare diseases. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey, USA. PTC Therapeutics Inc offers various products and solutions to treat diseases and conditions that are often neglected due to their rarity. These products are offered in three main areas: transcriptional regulation, DNA modification, and RNA technology. The products range from drugs to diagnostic tests to medical devices. In the transcriptional regulation division, PTC Therapeutics Inc is working on the development of small molecule drugs to regulate genes associated with various genetic diseases such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The most well-known product developed in this area is Translarna (Ataluren), which is approved for the treatment of Duchenne muscular dystrophy. The second area, DNA modification, focuses on developing therapies to correct targeted mutations in the genome. This includes the CRISPR/Cas9 system, which enables targeted genome editing. Along with RNA technology, which is the focus of the third area of the company, new possibilities for treating rare diseases are emerging. PTC Therapeutics Inc has already entered into various collaborations with biotech companies such as GenEdit, Censa Pharmaceuticals, and Beam Therapeutics. Another important core product of PTC Therapeutics Inc is the SMA360 diagnostic test, which aims to identify newly diagnosed infants and toddlers with spinal muscular atrophy (SMA). SMA360 is being developed in collaboration with Invitae and Biogen, and it enables fast and precise diagnosis of SMA. Due to its advanced pipeline and diversified product portfolio, PTC Therapeutics Inc has already achieved several milestones. In 2018, the company received approval for Emflaza in the US, a drug for the treatment of DMD. Further clinical trials are in the development phase. In terms of PTC Therapeutics Inc's business model, the development and commercialization of therapies for rare diseases are an important part. PTC Therapeutics Inc has a diversified product portfolio consisting of drugs, diagnostic tests, and medical devices. The company also collaborates with other companies in the biotech industry and partners with startups and universities in the research and development field. PTC Therapeutics Inc has experienced impressive growth in recent years and has the potential to develop and implement innovative therapies and solutions for rare diseases. The company has not only drawn interest in the industry but also from investors and is facing promising challenges in the future.

The expected revenue of PTC Therapeutics is 1.18 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PTC Therapeutics is 46.62 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PTC Therapeutics is currently 127.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PTC Therapeutics stock.

The price-to-sales ratio (P/S) of PTC Therapeutics is currently 5.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PTC Therapeutics stock.

The Eulerpool Quality Score for PTC Therapeutics is 7/10.

The ISIN of PTC Therapeutics is US69366J2006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of PTC Therapeutics is A1W0MW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of PTC Therapeutics is PTCT. The ticker symbol is used to trade PTC Therapeutics shares on the stock exchange.

PTC Therapeutics paid dividends every year for the past 0 years.

PTC Therapeutics is assigned to the 'Health' sector.

The dividends of PTC Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of PTC Therapeutics

Our stock analysis for PTC Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PTC Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

PTC Therapeutics Stock
PTC Therapeutics Revenue→
PTC Therapeutics Stock
PTC Therapeutics Net Income→
PTC Therapeutics Stock
PTC Therapeutics P/E→
PTC Therapeutics Stock
PTC Therapeutics P/S→
PTC Therapeutics Stock
PTC Therapeutics EBIT→
PTC Therapeutics Stock
PTC Therapeutics Dividend→
PTC Therapeutics Stock
PTC Therapeutics Directors Dealings→
PTC Therapeutics Stock
PTC Therapeutics Stocks→
PTC Therapeutics Stock
PTC Therapeutics Market capitalization→
PTC Therapeutics Stock
PTC Therapeutics Debt→
PTC Therapeutics Stock
PTC Therapeutics Liabilities→
PTC Therapeutics Stock
PTC Therapeutics Equity→
PTC Therapeutics Stock
PTC Therapeutics AAQS→
PTC Therapeutics Stock
PTC Therapeutics Employees→
PTC Therapeutics Stock
PTC Therapeutics ROE→
PTC Therapeutics Stock
PTC Therapeutics ROA→
PTC Therapeutics Stock
PTC Therapeutics ROCE→
PTC Therapeutics Stock
PTC Therapeutics News→
PTC Therapeutics Stock
PTC Therapeutics Analyst Price Targets→

Health Stocks

Pulike Biological EngineeringPT UBC Medical Indonesia TbkPulmatrixPsychemedicsPulmonxProvectus BiopharmaceuticalsPulse BiosciencesProtoKinetixPulsenmoreProthena CorporationPuma BiotechnologyProtext MobilityAll Stocks A–Z →